Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hereditary hemochromatosis.

Massimo Franchini1, Dino Veneri

  • 1Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona, Italy. massimo.franchini@mail.azosp.vr.it

Hematology (Amsterdam, Netherlands)
|July 16, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An unusual case of sodium citrate-dependent artifactual platelet count.

Interventional medicine & applied science·2022
Same author

Pathogenesis of immune thrombocytopenia in common variable immunodeficiency.

Autoimmunity reviews·2020
Same author

Is triple-positive serology for Epstein-Barr virus (VCA-IgG, VCA-IgM, EBNA-IgG) a specific feature of angioimmunoblastic T-cell lymphoma?

Tumori·2019
Same author

Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial.

Haematologica·2019
Same author

Calcium-Dependent Src Phosphorylation and Reactive Oxygen Species Generation Are Implicated in the Activation of Human Platelet Induced by Thromboxane A2 Analogs.

Frontiers in pharmacology·2018
Same author

Primary sphenoid lymphoma: Focus on imaging.

Tumori·2018
Same journal

Raloxifene inhibits the proliferation of pediatric acute myeloid leukemia by targeting the ANP32B gene and regulating C-MYC expression.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Characterization of a novel α-thalassemia deletion (Dongxing deletion; --<sup>DX</sup>) by CNV-seq in a Chinese female with Hb H disease: a case report.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study.

Hematology (Amsterdam, Netherlands)·2026
Same journal

Relationship between major depressive disorder and venous thromboembolism: a five-ancestry genetic analysis.

Hematology (Amsterdam, Netherlands)·2026
See all related articles

Hereditary hemochromatosis (HH) is an iron overload disorder. Early detection via transferrin saturation and ferritin tests, followed by phlebotomy treatment, ensures normal life expectancy for patients.

Area of Science:

  • Internal Medicine
  • Genetics
  • Molecular Medicine

Background:

  • Hereditary hemochromatosis (HH) involves progressive iron overload, potentially causing irreversible organ damage.
  • Molecular medicine advancements have refined understanding of HH pathophysiology and diagnosis.
  • Timely intervention is crucial for managing HH and preventing severe complications.

Purpose of the Study:

  • To summarize the current understanding of hereditary hemochromatosis.
  • To highlight key diagnostic markers and treatment strategies for HH.
  • To emphasize the importance of early detection and intervention in HH management.

Main Methods:

  • Review of current literature on hereditary hemochromatosis.
  • Analysis of diagnostic methods, including transferrin saturation and serum ferritin.

Related Experiment Videos

  • Evaluation of therapeutic phlebotomy as a primary treatment.

    • Main Results:

    • Transferrin saturation and serum ferritin remain the most reliable indicators for HH detection.
    • Therapeutic phlebotomy is the established primary treatment for HH.
    • Early initiation of phlebotomy before irreversible organ damage leads to normal life expectancy.

    Conclusions:

    • Hereditary hemochromatosis requires prompt diagnosis and treatment.
    • Effective management through phlebotomy can normalize life expectancy.
    • Continued research in molecular medicine enhances HH diagnosis and treatment strategies.